Another study involving around 3,000 breast cancer patients found that increased TIL counts exerted a survival benefit with an improved response to neoadjuvant chemotherapy in TNBC and HER2-enriched mammary tumors (95). This evidence concerns the gene ERBB2 and breast carcinoma.